Study identifies new biomarkers for prenatal risk assessment

NewsGuard 100/100 Score

NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that the American Journal of Perinatology has published the results of a blinded, retrospective study of 48 asymptomatic, healthy pregnant women that demonstrates the feasibility of assessing biomarkers associated with blood based microvesicles/exosomes for spontaneous preterm birth (SPTB) risk. The study describes a new library of statistically valued biomarkers for prenatal risk assessment that were identified at week 15-17 of gestation.

"The use of circulating extracellular microparticles as biomarkers is being intensely examined in multiple diseases. This study reflects the first in-depth proteomic evaluation of microparticle biomarkers as potential early warning signals of SPTB," said lead author Alan M. Ezrin, Ph.D. "A key finding was a common subset of differentiating biomarkers identified in both first pregnancy and second pregnancy subgroups, which opens the potential for use in a broad group of patients." The blinded study identified 18 such proteins of priority interest, with various multiplex combinations of markers accurately correlating 41-47 of the 48 cases to the respective SPTB or term-delivering cohort, at varying probability of error values of p<0.05 or better. NX Prenatal has undertaken further studies that may enable the clinical use of such markers for early risk stratification, understanding the pathophysiology of SPTB, and possibly the development of effective prevention strategies.

"A non-invasive test that can reliably provide enhanced preterm birth risk information prior to the week 16-20 optimal intervention initiation period would be a significant new tool for physicians and pregnant moms," commented co-author Dr. Baha Sibai, of the University of Texas Health Science Center at Houston. These findings are of importance relative to addressing the global problem of preterm birth which affects one in eight U.S. women and 15 million women globally each year – accounting for 75% of perinatal deaths and over 1 million newborn deaths each year.

Source:

NX Prenatal Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Esketamine after childbirth cuts risk of postnatal depression by three-quarters